Linden is a Senior Portfolio Manager at Candriam, managing biotechnology and oncology strategies since 2024.
Prior to joining Candriam, she was the lead manager of a biotech fund at AXA IM as well as the head of their healthcare franchise and a member of the UK Executive Committee. She brings over two decades of buy-side and sell-side experience in biotechnology. Linden started her career at Goldman Sachs in 2003, establishing technical expertise in healthcare, before moving on to a biotech hedge fund at start-up stage and subsequently to AXA Investment Managers in 2011.
Linden holds a BS (Hons) in Medical Microbiology from the University of Edinburgh. She has been a CFA Charterholder since 2011.
Discover the latest articles by Linden Thomson, CFA
ESG, SRI, Healthcare, Servaas Michielssens, Linden Thomson
I prezzi delle azioni del settore sanitario tendono a riflettere una certa trepidazione prima e subito dopo le elezioni presidenziali statunitensi, tuttavia nelle ultime cinque elezioni il settore ha registrato performance migliori nei 12 mesi successivi alle elezioni.
Q&A, Healthcare, Linden Thomson, Servaas Michielssens
Biotech investing: is there a doctor in the house?
Servaas Michielssens e Linden Thomson rispondono alle
domande degli investitori in merito a un settore in cui
l’approfondita conoscenza specialistica costituisce un
prerequisito per ottenere un successo costante nella selezione
dei titoli.
Oncology, Q&A, Servaas Michielssens, Linden Thomson, Equities
Investing in oncology: forewarned is forearmed
Rudi Van Den Eynde, Co-Head of Thematic Global Equity, e Linden Thomson, CFA, Senior Portfolio Manager, spiegano agli investitori l’approccio che hanno utilizzato per creare e sviluppare una strategia di investimento nel settore azionario globale dell’oncologia.